BoobyBiome Ltd.. (8/22/24). "Press Release: BoobyBiome Secures £1.6M Innovate UK Biomedical Catalyst Grant for Groundbreaking Synbiotic Research". London.

	Region	United Kingdom (GB)
	Organisation	BoobyBiome Ltd.
	Organisation 2	Innovate UK
	Group	United Kingdom (GB) (govt)
	Product	BIOTECH
	Product 2	business development (state/region)
	Person	Mapstone, Lydia (BoobyBiome 202408 CEO + Co-Founder)
	Person 2	Jones, Sioned Fôn (BoobyBiome 202408 COO + Co-Founder)

BoobyBiome, a pioneering biotechnology company, has been awarded a £1.6 million Biomedical Catalyst: Industry-led R&D grant from Innovate UK. Only 30 companies out of 358 applications were successful in meeting the strict criteria for funding from the £17.8M pot. This significant funding will support the rigorous testing and scale-up of BoobyBiome's innovative breast milk-derived Synbiotic for infants.

"We are delighted to receive this substantial grant from Innovate UK," said Dr Lydia Mapstone, CEO and Co-founder."This funding will be instrumental in advancing our research and bringing our game-changing Synbiotic closer to market, helping us deliver on our mission to provide beneficial microbes to infants at risk of developing an unhealthy gut."

Developed from the Institute of Child Health, Great Ormond Street Hospital, BoobyBiome’s Synbiotic has been engineered to closely match the breast milk microbiome. It contains a consortium of proprietary bacterial strains isolated from breast milk, selected for their ability to reduce inflammation and train the immune system. This exciting project is a collaborative effort with Dr Marie Lewis and her experienced team at the University of Reading, where the Synbiotic will undergo comprehensive testing to prepare for clinical testing.

“Our collaboration with the University of Reading will ensure that our product is rigorously tested and optimised, providing the best possible outcomes for infant health." added Dr Tara O’Driscoll, CTO and Co-founder.

In addition to the grant, BoobyBiome is proud to welcome new investors, including Evenlode Investment, Kayan Ventures, and a group of angel investors. Their expertise and investment will help expedite the launch of BoobyBiome's groundbreaking synbiotic, driving forward the mission to transform infant health on a global scale.

"We are excited to have the backing of such esteemed investors as we continue to innovate and expand our product offerings. Together, we are committed to making a positive impact on infant health globally." said Dr Sioned Jones, COO and Co-founder.

BoobyBiome is dedicated to advancing scientific research and developing products that address critical health needs. With the support of Innovate UK, the University of Reading, and new and existing investors, BoobyBiome is well-positioned to revolutionise infant feeding and contribute to the well-being of future generations.

About BoobyBiome

BoobyBiome is a biotechnology company that is dedicated to improving infant health and well-being. Their research focuses on developing evidence-based strategies to promote healthy microbial colonisation in infants and prevent common infant health issues.The company's mission is to empower parents to make informed decisions about their infant's health and to provide them with innovative tools they need to support their baby's development.

For more information about BoobyBiome and its innovative solutions, please visit www.boobybiome.com.

Media Contact

Email: info@boobybiome.com
Phone: +447806761756

Record changed: 2024-08-22

Picture Berlin Partner Top News CareSyntax Raises $180m Funding 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]